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a b s t r a c t 
Germ-cell-tumours (GCTs) are heterogeneous and management is complex. The current conventional biomark- 
ers, alpha-fetoprotein and human-chorionic-gonadotropin (HCG), have limited utility for diagnosis/follow-up as 
secretion is restricted to specific malignant-GCT subtypes and long half-life can make interpretation and clinical 
decision-making challenging. We sought to identify circulating microRNAs that reflected choriocarcinoma dis- 
ease activity more accurately than HCG in a metastatic primary mediastinal nonseminomatous-GCT (PMNSGCT) 
case with elevated diagnostic serum HCG ( > 250,000 U/L), consistent with pure choriocarcinoma. We undertook 
comprehensive microRNA profiling ( n = 754 microRNAs) using two 384-well TaqMan Low-Density-Array cards in 
16 serum samples; 10 from PMNSGCT diagnosis/follow-up and six controls. Key findings underwent confirmatory 
qRT-PCR. We identified a serum panel of choriocarcinoma-specific ‘chromosome-19-microRNA-cluster’ (C19MC) 
microRNAs that were highly elevated at diagnosis but fell rapidly on treatment and normalised before the sec- 
ond full chemotherapy course. We also re-confirmed serum elevation of the previously identified malignant-GCT 
marker miR-371a-3p at diagnosis. These circulating microRNA markers reflected choriocarcinoma disease activ- 
ity more accurately than serum HCG and real-time knowledge would have assisted clinical decision-making. With 
further study, these microRNA markers will facilitate future management of such patients and are likely to result 











































GCCC International Germ Cell Consensus Classification 
iRNA microRNA 
PVM non-pulmonary visceral metastases 
MNSGCT primary mediastinal nonseminomatous-GCT 
ntroduction 
Germ-cell-tumours (GCTs) are classified into seminoma and non-
eminomatous tumours (NSGCTs), the latter comprising the malig-
ant subtypes yolk-sac-tumour, embryonal carcinoma and choriocarci-
oma (CHC), in addition to teratomas, which show extensive somatic∗ Corresponding authors at: Department of Pathology, University of Cambridge, Te
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ifferentiation [1] . The conventional biomarkers alpha-fetoprotein
AFP), human-chorionic-gonadotropin (HCG) and lactate dehydroge-
ase (LDH) have limited utility for the diagnosis and follow-up of
alignant-GCTs [2] . LDH is very non-specific and secretion and detec-
ion of AFP and HCG in body fluids is restricted to specific subtypes, with
evels raised predominantly in tumours containing yolk-sac-tumour and
HC, respectively [2] . Even where levels of AFP and/or HCG are ele-
ated, clinical issues remain. These include the long half-lives of both
FP ( ∼5–7 days) and HCG ( ∼12–36 h) and their limited specificity,
hich may make clinical interpretation complicated [3 , 4] . Therefore,
ven in patients where these biomarkers are elevated at diagnosis, mak-
ng optimal management decisions may be challenging. 
Patients with primary mediastinal NSGCTs (PMNSGCTs) are classi-
ed into the International Germ Cell Consensus Classification (IGCCC)
oor-risk group, irrespective of any other additional risk factors, due
o their inferior prognosis [5] . Overall, this described IGCCC cohort
ad 48% five-year survival [5] , although current survival is marginallynnis Court Road, Cambridge CB2 1QP, United Kingdom. 
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e  etter. Poor outcomes for PMNSGCT patients have been confirmed in
ubsequent independent series [6 , 7] . Management is complex, particu-
arly for PMNSGCT patients with very high diagnostic serum HCG levels,
onsistent with a pure CHC. Issues include delayed diagnosis, with GCT
ot considered in a timely fashion, and thus AFP/HCG levels only re-
uested after pathological confirmation [8] . In addition, there is a high
isk of sudden respiratory decompensation [9] and/or catastrophic pul-
onary [10 , 11] or cerebral [12 , 13] haemorrhage in such patients on ini-
ial instigation of treatment, known as ‘choriocarcinoma syndrome’ [9] .
n such patients, close assessment in a tertiary centre intensive care set-
ing is warranted [9] . Furthermore, following induction chemotherapy,
rimary mediastinal surgery is important in patients with PMNSGCT in
rder to guide subsequent management [14] . However, the long half-
ives of AFP/HCG make assessment of when to perform such surgery
ifficult [14] . Optimising management and timing of these interven-
ions may well improve outcomes for PMNSGCT patients [14] , including
hose with CHC [9] . 
Improved biomarkers, which are highly sensitive and specific at
alignant-GCT diagnosis and which accurately reflect disease status
uring treatment and in follow-up, would therefore address such un-
et clinical needs. Over the last decade, microRNAs (miRNAs) have
merged as a new generation of biomarkers for malignant-GCTs [15] .
iRNAs are short, non-protein coding RNAs that are highly stable and
uitable for diagnosis and disease-monitoring [16] . MiRNAs from the
iR-371 ∼373 (chromosomal locus 19q13.41) and miR-302/367 (4q25)
lusters are universally over-expressed in malignant GCT tissue samples
1] . Levels of miRNAs from these clusters are elevated in the serum at
alignant-GCT diagnosis, decrease with treatment and increase at ma-
ignant relapse [17–24] , and their role has recently been subject to a
omprehensive review [15] . 
Other miRNA expression changes reflective of different malignant-
CT subtypes also occur in the tissues, such as overexpression of
iRNAs from the ‘chromosome-19-microRNA-cluster’ (C19MC, or miR-
15 ∼526 [1] ) in embryonal carcinoma [1] . C19MC is the largest human
iRNA gene cluster, containing > 40 miRNAs. Intriguingly, C19MC is co-
ocated within 100 kb of the miR-371 ∼373 cluster and occurs uniquely
n primates [25] . C19MC is expressed at high levels in placental tis-
ues [26] and miRNAs from this cluster have also been found to be
t high levels in the bloodstream in pregnancy, both in physiological
27] and pathological states, e.g. pre-eclampsia [28] and gestational-
rophoblastic-neoplasia (GTN) [29] . Given the similar pathological tro-
hoblastic (placental-like) appearances between GTN and CHC, we hy-
othesised that in addition to miR-371 ∼373 miRNAs, C19MC miR-
As may also offer value as circulating biomarkers for this partic-
lar malignant-GCT subtype. Previously, three C19MC miRNAs were
uantified in testicular GCT and control tissues and just one (miR-
17a-3p) selected for serum assessment from affected patients [30] .
f note, only two patients had a modest quantifiable CHC compo-
ent (mixed malignant-GCTs containing 30% and 10% CHC) and no
atients in the cohort had pure CHC [30] , so the direct contribution
o the circulating miRNA profile from pure CHC alone could not be
ssessed. 
Here, using unbiased comprehensive miRNA profiling, we sought to
dentify circulating miRNAs that reflected CHC disease activity more
ccurately than HCG in a widely metastatic primary mediastinal non-
eminomatous GCT (PMNSGCT) case with elevated diagnostic serum
CG level ( > 250,000 U/L), consistent with pure CHC. In future, with
urther study and validation, real-time knowledge of miRNA markers
ay facilitate clinical management of such patients. 
ase report 
A 13-year-old male presented with a short history of cough and
aemoptysis. He was well on clinical examination, with normal res-
iratory findings. Chest X-ray revealed a large mediastinal mass and
ultiple pulmonary metastases up to 50 mm in diameter ( Fig. 1 A).T confirmed the above findings ( Fig. 1 B), with the mediastinal mass
44 mm in maximal coronal diameter, and revealed additional non-
ulmonary visceral metastases (NPVM) in the spleen and kidneys.
loods revealed normal full blood count (FBC), urea and electrolytes
U&E) and liver function tests (LFTs). Lactate dehydrogenase (LDH) es-
imation (350 U/L) was within the reference range. Serum HCG was el-
vated at 260,760 U/L (range 0.0–4.0) ( Fig. 2 A). Serum AFP was nor-
al ( < 2; range 0–10 kU/L). Coagulation studies revealed a prolonged
rothrombin time (16.7 s; range 10.4–13.3), which was aggressively
orrected with intravenous vitamin K and fresh frozen plasma. Further
taging revealed disease in the L3 vertebral body and multiple cerebral
etastases ( Fig. 1 C). The diagnosis was made of a widely metastatic
ediastinal CHC which fell into the IGCCC poor-risk group [5] due to
hree independent risk factors: mediastinal primary, HCG > 50,000 U/L,
nd NPVM. 
Due to the high decompensation and/or life-threatening haemor-
hage risk, central venous access was obtained and emergency ‘Em-
P’ chemotherapy commenced on intensive care on the day of pre-
entation, with two days of cisplatin (20 mg/m 2 /day) and etoposide
100 mg/m 2 /day) [31] delivered. Early chest X-ray performed on day
 revealed an apparent interval increase in size of the bilateral multi-
le pulmonary masses ( Fig. 1 D) although the patient remained clinically
ell. The standard treatment for IGCCC poor-risk patients is four courses
f ‘BEP’ ( B leomycin, E toposide and cis P latin) chemotherapy. However,
leomycin was substituted for ifosfamide and four full courses of ‘PEI’
or ‘VIP’) chemotherapy [cis P latin, E toposide ( V P-16) and I fosfamide]
32 , 33] delivered for multiple reasons. Firstly, the large mediastinal
rimary and multiple pulmonary lesions would have made assessment
or bleomycin toxicity challenging, by significantly influencing baseline
ulmonary function test results [34] if performed, obscuring possible
hest X-ray changes, and in view of the pre-existing cough. Secondly,
iven patients with PMNSGCTs have a high rate of postoperative pul-
onary failure and mortality from major thoracic surgical procedures
ollowing the use of BEP, some clinicians prefer to use PEI/VIP [35] .
hirdly, multiple metastatic CNS lesions were present, and PEI is stan-
ard treatment for CNS NSGCTs as ifosfamide is known to have good
NS penetration [36] . 
Four PEI/VIP courses were therefore delivered with GCSF support
rom day (d) 10 at 18–20 day intervals, upon count recovery. The pa-
ient remained clinically well throughout, with resolution of cough and
aemoptysis within two weeks of commencing treatment. HCG estima-
ion fell to 966.1 U/L on d28 (d1 of the second course of PEI chemother-
py), 369.3 U/L (d48; d1 of cycle 3) and 111.6 U/L (d66; d1 of cycle 4).
owever, the HCG level was still elevated at 56.1 U/L following the last
hemotherapy course on d82 ( Fig. 2 A). Furthermore, radiological imag-
ng revealed only modest reduction in mediastinal primary size and per-
istence of multiple pulmonary metastases ( Fig. 3 A). MRI head revealed
nly small foci of blood degradation products in the region of previ-
us metastases, consistent with treatment response. Multidisciplinary
iscussion of these biochemical and chest findings at an outside institu-
ion (where surgery was planned) led to suggestions that surgery to the
ediastinal primary might be cancelled and second-line chemotherapy
or refractory disease instituted instead. However, in view of evidence
hat surgery in such cases should proceed regardless of conventional
umour marker levels, unless they are genuinely rising [14] , surgery
as undertaken on d94 following further discussion between the two
nstitutions. Complete resection of the primary mediastinal mass was
chieved ( Fig. 3 B). Of note, pathological examination of the mediasti-
al resection specimen revealed complete necrosis only, with no evi-
ence of viable disease. Serum HCG levels continued to fall slowly fol-
owing surgery and finally normalised by d138 ( Fig. 2 A). Consequently,
n expectant ‘watch-and-wait’ surveillance approach was adopted. The
atient’s HCG levels remained within the reference range and chest radi-
logical findings gradually resolved ( Fig. 3 C/D); pulmonary metastases
ere no longer visible on chest X-ray performed over two years after the
nd-of-treatment ( Fig. 3 D). The patient remains well, 45 months from
M.J. Murray, S. Smith, D. Ward et al. Translational Oncology 14 (2021) 100904 
Fig. 1. Radiological imaging at the time of presentation of the patient with a metastatic primary mediastinal nonseminomatous germ-cell-tumour (PMNSGCT). 
A) Plain chest X-ray on the day of presentation showing mediastinal mass and multiple pulmonary metastases; B) Representative axial view of the CT chest scan 
confirming findings in A); C) Representative axial view of the CT head scan revealing cerebral metastases with surrounding vasogenic oedema; D) Plain chest X-ray 





































s  nitial presentation and 41 months following end of treatment, with an
xpected survival now in excess of 93% [37] . 
aterials and methods 
tudy rationale and serum samples analysed 
Given the relatively long half-life of HCG, generally ∼12–36 h [3 , 4] ,
nd the lack of correlation between radiological appearances and patho-
ogical response to chemotherapy in PMNSGCTs [14] , we sought to iden-
ify circulating miRNAs that may offer a diagnostic and longitudinal
rofile more accurately reflecting disease activity, particularly at d82
hen assessing the patient for primary mediastinal surgery, when the
CG was still elevated ( Fig. 2 A) and radiology showed persistent bilat-
ral pulmonary metastases ( Fig. 3 A). 
To this end, we undertook initial screening using comprehensive
iRNA profiling of clinical serum samples in the index case at diagnosis
nd key subsequent time-points, leftover after routine clinical use, and
ompared results with serum samples from non-cancer control patients.
ey findings were validated by targeted Taqman qRT-PCR in triplicate.
he study received approval from the Cambridge Local-Research-Ethics-ommittee (reference 01/128) and was performed with full informed
arental consent. All experimental steps were MIQE compliant [38] . 
In total, we analysed 16 serum samples, namely 10 test samples from
he index case and six controls. The comprehensive circulating miRNA
rofiling study (initial screening phase) comprised eight test samples;
hree separate individual samples (biological replicates) at original di-
gnosis (d0) and then the five time-points d28, d45, d66, d101 and d341.
n addition, serum samples from a group of age-matched control subjects
ithout tumours ( n = 4) were utilised for comparison. For the targeted
rofiling study (validation phase), as well as the time-points above, two
dditional available serum samples from d17 and d181 time-points were
nalysed. Two of the three diagnostic (d0) test samples, and three of
he four control samples, used in the comprehensive profiling study had
ufficient serum available for the subsequent targeted profiling. These
hree existing controls were therefore supplemented by an additional
wo age-matched control samples for this validation phase. 
ample processing 
As part of standard clinical care, blood was sampled in serum-
eparator tubes, before processing and centrifugation within four hours
M.J. Murray, S. Smith, D. Ward et al. Translational Oncology 14 (2021) 100904 
Fig. 2. Longitudinal circulating biomarker levels from diagnosis, through treatment and into follow-up (d341) for the patient with a metastatic PMNSGCT. A) Serial 
serum total and free beta-subunit human-chorionic-gonadotropin (HCG) levels shown. Horizontal dotted lines represent upper limit of reference range for total HCG 
(red) and free beta subunit HCG (blue) of HCG. For HCG values below the detection range ( < 2.0 for total and < 0.2 for free beta subunit), arbitrary values of 1 
and 0.15 were assigned, respectively. Key: Em-EP = emergency cisplatin-etoposide chemotherapy; PEI = cisplatin, etoposide and ifosfamide chemotherapy. B) Serial 
miRNA levels at time-points from the comprehensive profiling (screening phase) study. Data for the seven clustered C19MC miRNAs are shown. The first values 
represent the mean miRNA level obtained from analysis of the three independent serum samples taken at the time of original diagnosis (d0), assessed in singlicate. 
Subsequent levels are from time-points d28, d45, d66, d101 and d341, assessed in singlicate. All levels were normalised using the geometric mean approach. For 
miRNA values < 1, an arbitrary value of 1 was assigned. Horizontal dotted lines represent maximum level (orange), mean + 2SDs (blue), and mean level (black) of the 
control samples, across all seven C19MC miRNAs. 
M.J. Murray, S. Smith, D. Ward et al. Translational Oncology 14 (2021) 100904 
Fig. 3. Radiological imaging with plain chest X-rays in follow-up for the patient with a metastatic PMNSGCT. A) At the end of the four full courses of PEI/VIP 
chemotherapy (d82) revealing only modest reduction in the size of the mediastinal primary and the persistence of multiple pulmonary metastases; B) After surgery to 
the mediastinal primary on d94; C) Twelve months following end of treatment, showing gradual resolution of the pulmonary metastases, consistent with pathology 
of the mediastinal primary showing complete necrosis; D) 30 months from initial presentation and more than 27 months following end of treatment, finally showing 




























e  f receipt, as described [21] . After routine clinical measurements,
amples were kept at 4 °C before residual serum was frozen and stored
t − 80 °C [21] . Only samples without macroscopic evidence of haemol-
sis were used [21 , 39] , to avoid technical variations due to intracellular
iRNA release from red-blood-cells [40] . 
NA isolation and initial sample quality control 
RNA from 200 μl of thawed serum was isolated using the Qiagen
iRNeasy serum/plasma kit (catalogue number 217184), with addi-
ion of Sigma MS2-carrier-RNA to improve RNA yield [21 , 41] . In ad-
ition to a fixed quantity of exogenous non-human spike-in cel-miR-39–
p (Qiagen, catalogue number 219610), ath-miR-159a (Thermo-Fisher-
cientific, catalogue number 4464066) was also added, as per best prac-
ice [4 , 38] , to allow subsequent measurement of RNA extraction ef-
ciency [21 , 41] , as RNA concentration measurements are unreliablen RNA samples extracted from serum due to low abundance [42 , 43] .
otal RNA was eluted from columns with either 15 μl or 100 μl [21] of
uclease-free-water, for comprehensive screening and targeted valida-
ion phases, respectively. Total RNA was stored at − 80 °C until use. For
amples eluted in 100 μl, quality control checks were performed by sin-
leplex qRT-PCR for the exogenous (cel-miR-39–3p and ath-miR-159a)
nd endogenous (miR-30b-5p, miR-23a-3p and miR-451a) miRNAs, to
xclude any technical issues or samples with substantial haemolysis, as
escribed [21 , 41] . For samples eluted in 15 μl, 1 μl of RNA eluate was
iluted to a final volume of 26 μl and then 5 μl of this mix was used as
emplate for each individual reverse-transcription reaction. 
omprehensive circulating miRNA profiling – reverse-transcription step 
Reverse-transcription (RT) was undertaken with 3 μl of total RNA for
ach sample using the Life-Technologies TaqMan microRNA Reverse-
























































































































ranscription Kit (catalogue number 4366596) using Life-Technologies
egaplex TM -RT-Primers-Human-Pool-A (v2.1) or Pool-B (v3.0) (cata-
ogue number 4444750, comprising both pools, overall comprising 754
nique miRNAs plus four control assays). The final volume was 7.5 μl for
ach reaction. For no-template-control (NTC) reactions, 3 μl of nuclease-
ree-water was used instead of RNA. Following a 5 min incubation on ice
t 4 °C, samples underwent RT for 40 cycles on an MJ-Research-Peltier-
hermal-Cycler PTC-225 machine, comprising 16 °C for 2 min, 42 °C for
 min and 50 °C for 1 second, and then 85 °C for 5 min to complete the
eaction prior to a final hold at 4 °C. Complementary-DNA (cDNA) was
hen stored at − 20 °C until further use. 
omprehensive circulating miRNA profiling – pre-amplification PCR step 
Pre-amplification was undertaken with 5 μl of cDNA for each sam-
le, as per the manufacturer’s instructions. Pre-amplification primers
or Human-Pool-A (v2.1) or Human-Pool-B (v3.0) were used (2.5 μl)
ith Life-Technologies TaqMan PreAmp-Master-Mix (catalogue num-
er 4391128) (12.5 μl) and nuclease-free-water (5 μl), to make a final
eaction volume of 25 μl. Following 5 min incubation on ice at 4 °C,
amples underwent pre-amplification PCR on an MJ-Research-Peltier-
hermal-Cycler PTC-225 machine, comprising initial hold steps of 95 °C
or 10 min, 55 °C for 2 min and 72 °C for 2 min prior to 15 cycles of
5 °C for 15 s and 60 °C for 4 min, before 100 °C hold for 10 min to
omplete the reaction prior to a final hold at 4 °C. The 25 μl of neat
re-amplification product was then stored at − 20 °C until further use. 
omprehensive circulating miRNA profiling – final amplification PCR step 
This was undertaken on two 384-well TaqMan Low-Density-Array
&B cards (catalogue number 4444913) with reaction volumes as per
he manufacturer’s instructions. In short, 9 μl of neat pre-amplified
roduct (to maximise assay sensitivity) for each sample was added
o 425 μl of TaqMan Universal-PCR-Master-Mix, No-AmpErase-UNG
Applied-Biosystems) and 416 μl of nuclease-free-water to make a fi-
al volume of 850 μl, and the cards were then loaded as per the man-
facturer’s instructions. Each card contained 377 unique assays (cor-
esponding to 754 unique miRNAs across both cards, assessed in singli-
ate) and four controls, namely three candidate endogenous (U6 snRNA,
NU44, and RNU48) assays and one exogenous (ath-miR-159a) as-
ay. PCR was carried out on an Applied-Biosystems 7900HT-Fast-Real-
ime-PCR-System using a TaqMan R ○-Array-Micro-Fluidic-Card Thermal-
ycling-Block and associated standard PCR protocol. 
omprehensive circulating miRNA profiling – data analysis, normalisation 
nd identification of biomarkers 
All data analysis was conducted with the R statistical computing
anguage using the HTPCR, ggplot2 and tidyr packages. The data were
rst filtered to exclude any samples which failed quality control (none
ailed this step) and miRNAs which were undetectable or invariant (225,
9.8%). After comparing normalisation strategies, a geometric mean ap-
roach was employed for all downstream analysis. To find groups of co-
xpressed miRNAs using unbiased methodology, we employed k-means
lustering with silhouette analysis [44] . Silhouette analysis for k be-
ween 2 and 40 yielded a maximum score at k = 7; this value was used
n the k-means clustering. We examined any clusters in detail to find
hose whose expression profile most closely matched the clinical course
f the patient in order to identify new candidate biomarkers. This was
chieved by using the mean expression value for each cluster to cal-
ulate the greatest decrease between diagnosis and subsequent time-
oints after treatment commenced. Cluster means were then selected
hich showed no significant increase after the initial decrease in ex-
ression. Next, raw Ct values were analysed to assess overall biomarker
bundance; miRNAs within clusters with raw Ct values > 30 at diag-
osis were excluded to ensure maximal assay sensitivity for remainingandidates. Mean diagnostic expression levels (taken from the three bi-
logical replicates) were compared with mean expression levels from
he control group to derive fold-changes. For the control group, mean,
aximum, and mean plus two standard deviation (mean + 2SD) levels
ere determined. The reference range was considered to be values up
o the mean + 2SD threshold. 
onfirmatory targeted miRNA profiling – reverse-transcription step 
We next undertook targeted assessment of selected miRNAs iden-
ified in the comprehensive discovery screening phase of the study in
he full longitudinal panel of serum samples from the index case, along
ith miR-517a-3p [30] . These were assessed along with the endoge-
ous housekeeping miRNA miR-30b-5p [17 , 21 , 24 , 39 , 45] , and the ex-
genous spike-in miRNAs cel-miR-39-3p and ath-miR-159a using tar-
eted qRT-PCR. Taqman assay-IDs for these primer/probes were as fol-
ows: miR-517a-3p (ID 002402), miR-517c-3p (001153), miR-519a-3p
002415), miR-515–5p (001112), miR-518d-5p (002389), miR-522-3p
002413), miR-30b-5p (000602), cel-miR-39–3p (000200) and ath-miR-
59a (000338). In addition, miR-371a-3p (ID 002124) was also assessed
n targeted profiling in diagnostic samples. We first performed a multi-
lexed RT step using the relevant TaqMan miRNA-specific stem-loop RT
rimers each diluted 1:50 with 1x Tris-EDTA buffer (pH 8.0) in an equal
ixture of each relevant RT primer, adapted from [22] , and using 5 μl
f RNA eluate. The final volume of 15 μl for each reaction underwent
T, as described above for the comprehensive miRNA profiling phase
bove. 
onfirmatory targeted miRNA profiling – pre-amplification PCR step 
For the pre-amplification step, reactions were multiplexed using the
elevant individual TaqMan assay probes, allowing greater assay sensi-
ivity and increasing the number of target miRNAs measured from the
mall starting volume, as described [22] . Briefly, an equal mix of all
0x TaqMan assay probes was prepared for each reaction and diluted
o 0.2x with 1x Tris-EDTA buffer (pH 8.0), as described [22] . The pre-
mplification reaction contained 25 μl of 2x TaqMan PreAmp-Master-
ix, 12.5 μl of the diluted TaqMan assay probe mix and 12.5 μl of mul-
iplexed cDNA product [22] . After heating to 95 °C for 10 min, 14 cycles
f 95 °C for 15 s and 60 °C for 4 min were run on a MJ-Research-Peltier-
hermal-Cycler PTC-225 machine [22] . The resulting reaction products
ere diluted 1:10 with nuclease-free-water to make a final volume of
00μl, sufficient to perform all subsequent singleplex final miRNA PCR
eactions in triplicate. 
onfirmatory targeted miRNA profiling – final amplification PCR step 
Nine μl of the diluted pre-amplified cDNA product was added to
0 μl of TaqMan 2x Universal-PCR-Master-Mix, No-AmpErase-UNG and
 μl of each individual 20x TaqMan assay probe, thereby maintaining
atios identical to those previously described [22] . All reactions were
erformed in triplicate. PCR was performed using the following condi-
ions: TaqMan activation (hold) 95 °C for 10 min, followed by 45 cycles
f denaturation (95 °C 15 s) and annealing/extension (60 °C for 1 min)
n a Realplex-Mastercycler. For both the targeted miRNA quantifica-
ion steps, the Ct threshold was set manually to 2000 fluorescence units
cross all PCR plates, as described [21] . MiRNAs with results within
wo Ct values of the NTC sample were classed as non-expressing, as de-
cribed [21] . Samples which gave no Ct value, or a Ct value of > 40, were
rbitrarily assigned a Ct value of 40. Mean diagnostic expression levels
taken from the two available biological replicates) were compared with
ean expression levels from the control group to derive fold-changes. As
or the comprehensive profiling study, mean, maximum, and mean + 2SD
evels were determined and the reference range was considered to be
alues up to the mean + 2SD threshold. 
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Table 1 
Candidate circulating miRNA biomarkers for the germ-cell-tumour subtype choriocarcinoma (CHC). The seven k-means clustered C19MC miRNA candidate biomark- 
ers are shown, plus miR-517a-3p identified from literature review. Data shown include formal miRBase accession number, Taqman probe ID, mean raw Ct value 
from the comprehensive miRNA profiling study (mean of three biological replicates from diagnosis, each measured in singlicate), and fold-change relative to the 
mean expression levels of the control group, and those miRNAs selected for subsequent targeted qRT-PCR with confirmatory diagnostic fold-change (mean of two 




number at miRBase 
( http://www.mirbase.org/ ) 
Mean raw Ct value 
(global profiling) 
Mean normalised 
fold-change vs . controls 
(global profiling) 
Selected for targeted 
qRT-PCR profiling 
Mean normalised 
fold-change vs . controls 
(targeted profiling) 
miR-517c-3p 001153 MIMAT0002866 22.7 2588 Yes 1401 
miR-519a-3p 002415 MIMAT0002869 22.4 4787 Yes 1569 
miR-518d-5p 002389 MIMAT0002864 26.8 4603 Yes 1578 
miR-515-5p 001112 MIMAT0002827 26.3 6527 Yes 1547 
miR-522-3p 002413 MIMAT0002868 24.7 8289 Yes 1016 
miR-517a-3p 002402 MIMAT0002852 22.8 4456 Yes 3540 
miR-517b-3p 001152 MIMAT0002857 26.7 5112 No N/A 
miR-518e-3p 002395 MIMAT0002861 25.8 2700 No N/A 


























































































l  esults 
In initial screening work on the comprehensive serum miRNA pro-
ling dataset, all samples passed quality control. After exclusion of un-
etectable/invariant miRNAs (225 from 754; 29.8%) and normalisation
trategy comparison, the geometric mean approach, using the remain-
ng 529 miRNAs (70.2%) from the two 384-well TaqMan Low-Density-
rray cards, was employed for all downstream analysis, as this was op-
imal. This number was very similar to the 568/741 miRNAs (76.7%)
sed for normalisation in our previous discovery microRNA profiling
tudy [39] . In addition, normalisation using the established single en-
ogenous miRNA miR-30b-5p [17 , 21 , 24 , 39 , 45] also gave very similar
esults, indicating its utility for subsequent targeted miRNA profiling. 
To find groups of co-expressed miRNAs using unbiased methodology,
e employed k-means clustering ( k = 7 clusters after silhouette analysis)
44] . A single cluster most closely matched the clinical course of the pa-
ient. This cluster contained an initial 10 miRNAs; three were excluded
s they had mean raw Ct values > 30 (namely miR-302d-3p, probe ID
00535, mean raw Ct 37.7; miR-200a-5p, 001011, 36.7; and miR-630,
01563, 32.6). The remaining seven miRNAs in this single cluster were
ll derived from the C19MC cluster at chromosomal locus 19q13.41,
amely miR-515–3p, miR-517b-3p, miR-517c-3p, miR-518d-3p, miR-
18e-3p, miR-519a-3p and miR-522-3p ( Table 1 ). These seven candi-
ate miRNAs were highly elevated at the time of CHC diagnosis ( Table 1 ,
ig. 2 B and Supplementary-Fig.-S1). Following treatment, levels of five
f these candidates, namely miR-517c-3p, miR-519a-3p, miR-518d-5p,
iR-515-5p and miR-522-3p had fallen to, and/or remained within, the
eference range by d28 and d45 of treatment, i.e. before/during the sec-
nd full course of chemotherapy ( Fig. 2 B, Supplementary-Fig.-S1). In
ddition, miR-517a-3p, selected from literature review [30] , also met
his criterion (Supplementary-Fig.-S1). These six miRNAs were there-
ore selected for subsequent targeted profiling, in triplicate, following
his comprehensive screening in singlicate. In addition, miR-371a-3p,
n established universal serum miRNA biomarker in malignant-GCTs
17 –24] , had an elevated circulating level at diagnosis, although more
odest than the fold-changes seen for the C19MC candidates ( Table 1 ),
nd was consequently only selected for confirmation in diagnostic sam-
les. We noted that two of the C19MC miRNAs selected for valida-
ion did show marginally elevated levels at subsequent time-points in
his comprehensive screening phase, performed in singlicate (namely
iR-518d-5p at d101 and miR-515-5p at d101/d341) ( Fig. 2 B, Supple-
entary Fig.-S1), hence the need for subsequent validation by triplicate
RT-PCR. 
Further confirmation by targeted qRT-PCR across all available time-
oints was performed for the six selected C19MC miRNA candidates.
his was an important next step, as targeted qRT-PCR was performed
n technical triplicate for each miRNA, whereas on the profiling cards,
P  ach miRNA was only represented once, and hence more prone to varia-
ion in levels. Circulating levels of all six of these C19MC miRNAs were
onfirmed to be highly elevated at diagnosis compared with the mean
f the control group ( Table 1 , Fig. 4 ). With the additional time-points,
e could confirm that levels of these miRNAs had normalised prior to
he start of the second course of chemotherapy (d17 and d28) and as a
anel remained low subsequently ( Fig. 4 ). Importantly, levels remained
ow at d82 ( Fig. 4 ) when the patient was being assessed for primary me-
iastinal surgery, when the serum HCG was still elevated ( Fig. 2 A) and
adiology showed persistent bilateral pulmonary metastases ( Fig. 3 A). In
ddition, we confirmed that miR-371a-3p showed elevated serum levels
t diagnosis ( Table 1 ). 
iscussion 
The clinical management of germ-cell-tumours (GCT) is complex due
o their heterogeneity [1] . This includes both gonadal and extragonadal
often relatively inaccessible) disease, different histological subtypes,
nd risk-groups with differing outcomes [4] . A major current issue is the
imited sensitivity and specificity of the current serum markers alpha-
etoprotein (AFP), human-chorionic-gonadotrophin (HCG) and lactate
ehydrogenase (LDH), which are only positive at diagnosis in ∼50% of
ases [4] . Even where positive at diagnosis, a further limitation includes
heir long half-lives, making optimal management decisions for patients
ifficult. 
Importantly, in this patient with a widely metastatic primary medi-
stinal nonseminomatous GCT (PMNSGCT) and diagnostic serum HCG
evel consistent with pure CHC, we identified a panel of C19MC miR-
As that were highly elevated at diagnosis. We also confirmed elevation
f the established miRNA marker miR-371a-3p [17 –24] . Levels of these
19MC miRNAs fell rapidly on treatment, normalising before the sec-
nd full course of chemotherapy and which, if available in real-time,
ould have facilitated clinical management. Here, we show that circu-
ating C19MC miRNA levels provided a much more accurate readout of a
ood early response to treatment than conventional markers/imaging.
onsistent with the very short circulating half-life ( << 12 h) [46] and
xcellent correlation with malignant-GCT disease activity reported for
iR-371a-3p e.g. [17 , 21 , 22 , 24 , 47] , we speculate that the successful and
ggressive early treatment approach pursued here reduced the viable
HC tumour cells to such low numbers that circulating C19MC lev-
ls were within the reference range prior to the second full course of
hemotherapy. Of note, the decay of C19MC miRNAs observed here ap-
ears even more rapid than for miR-371a-3p, which still showed a sig-
ificant decrease between the second and third chemotherapy courses
n malignant-GCT patients with stage 3 disease [17] . Furthermore, fol-
owing completion of induction chemotherapy with four full courses of
EI/VIP, surgery to remove the mediastinal primary is recommended for
M.J. Murray, S. Smith, D. Ward et al. Translational Oncology 14 (2021) 100904 
Fig. 4. Confirmation of targeted longitudinal circulating miRNA biomarker levels from diagnosis, through treatment and into follow-up for the patient with a 
metastatic PMNSGCT. Data shown for the six C19MC miRNAs identified in the comprehensive profiling study, namely miR-518d-5p, miR-519a-3p, miR-517c-3p, 
miR-515-5p and miR-522-3p and from literature review (miR-517a-3p). All levels were performed in technical triplicate and normalised to the established endogenous 
housekeeping miRNA miR-30b-5p. For miRNA values < 1, an arbitrary value of 1 was assigned. Horizontal dotted lines represent mean + 2SDs (blue), maximum level 




























fi  atients with PMNSGCT to assist subsequent management decisions, but
he prolonged half-life of AFP and HCG can make establishing the opti-
al timing of surgery difficult [14] . Here, when surgery was being con-
idered at d82, the serum HCG level was still raised ( Fig. 2 A) and chest
-ray showed minimal changes from diagnosis ( Fig. 3 A). As a result, the
utside surgical institution recommended that second-line chemother-
py for refractory disease be instituted. With our knowledge that surgery
hould proceed unless conventional markers were genuinely rising [14] ,
ur institution advocated strongly for surgery, which was performed on
94. This management is also consistent with a report which showed
hat < 10% of patients who presented with HCG levels > 50,000 kU/L
i.e. IGCCC poor-risk) had a normal HCG at the time of the fourth and
nal course of chemotherapy [48] . However, ∼50% of those patients
emained event-free despite no further chemotherapy, confirming thatalvage therapy should only be initiated if and when there is HCG pro-
ression [48] . Such clinical decision-making would therefore have been
acilitated by knowledge of the early normalisation of serum C19MC
iRNAs. Consistent with these observations, pathology of the resected
ediastinal mass showed complete necrosis. No further treatment has
een necessary, and the patient now has an expected survival of > 93%
37] . 
Previous study of circulating miRNAs for patients with the CHC
alignant-GCT subtype has been exceptionally limited. No previous
tudies have assessed patients with pure CHC. One study quantified
erum levels of the single C19MC miRNA miR-517a-3p, but only two
atients in the cohort had a quantifiable CHC component, both with
 30% involvement within a mixed malignant-GCT [30] . As exempli-
ed here, our identified panel of C19MC miRNAs, plus miR-517a-3p






















































































































30] and along with miR-371a-3p, offer potential advantages for mon-
toring patients with CHC, due to limitations of the accompanying el-
vated serum HCG levels, as well as for patients with embryonal car-
inoma [30] , who may be AFP/HCG marker negative. Future use of
erum miRNA markers to optimise management for malignant-GCT pa-
ients [15] , including those with PMNSGCTs [14] and/or pure CHC [9] ,
ill likely improve patient outcomes. Importantly, serum miRNAs are
oving from research promise towards clinical reality for the manage-
ent of patients with malignant-GCTs [15] . Of note, despite extensive
earches, there were no suitable publicly available datasets to extend
he observations described here at this stage. Hence, future work will
e needed to confirm the utility of our observations. 
In addition to the biomarker potential of these miRNAs [15] , they
ave a functional role in malignant GCT development and progression.
elective activation and expression of C19MC miRNAs in the nonsemi-
omatous malignant-GCT subtypes embryonal carcinoma and CHC is
ikely to confer additional clinical aggressiveness to these tumours when
ompared with their seminomatous counterparts, over and above that
rovided by universal miR-371 ∼373 and miR-302/367 overexpression
1] . MiRNAs regulate protein-coding gene expression through binding
o the 3 ′ untranslated region (3 ′ UTR) of messenger RNAs (mRNAs),
etermined primarily by the ‘seed’ region at nucleotide positions 2–7
2–7 nt). Intriguingly, many C19MC miRNAs contain the same 2–7 nt
eed region, namely ‘AAGUGC’, as miRNAs from the miR-371 ∼373 and
iR-302/367 clusters, and therefore have overlapping mRNA targets.
AAGUGC’ seed-containing miRNAs allow cells to continue unchecked
hrough the cell cycle, resulting in rapid cellular proliferation and a se-
ective growth advantage [49] . Altered C19MC expression has been de-
cribed in other tumours to date [25] and C19MC miRNAs may also act
hrough negative regulation of apoptosis [50] . Of note, expression lev-
ls of miR-371 ∼373 and C19MC miRNAs in malignant-GCT cells have
een shown to substantially increase upon development of cisplatin re-
istance, further demonstrating a key functional role for these short non-
oding RNAs [51] . The dysregulated expression of miRNAs observed in
alignant-GCTs could therefore potentially be targeted therapeutically,
n order to ultimately improve patient outcomes with poor-risk disease
52] . 
In summary, we describe a patient with a widely metastatic PMNS-
CT and findings consistent with a pure CHC, for whom associated clin-
cal challenges are described. We identify a panel of C19MC miRNAs, as
ell as miR-371a-3p, which were elevated at diagnosis. We show that
evels of the C19MC miRNAs fell rapidly on treatment and normalised
arly during chemotherapy treatment, reflecting CHC disease activity
ore accurately than HCG. Following further study, real-time knowl-
dge of these miRNA markers will facilitate future management of such
atients and are likely to result in improved clinical outcomes. 
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